Table II.
Reported cases of anaphylaxis per million doses of COVID-19 vaccines in the literature, evaluated independently by the authors and final consensus achieved.
| Anaphylaxis definition | Certainty | CDC COVID-19 Vaccine Task Force |
Non–COVID vaccines 2009-2011, USA4 |
|
|---|---|---|---|---|
| Pfizer-BioNTech December 14-23, 20202 |
Moderna December 21 2020-January 10, 20213 |
|||
| Brighton criteria (reported) | Levels 1-3 |
21 cases in 1,893,360 doses 11.1/million (95% CI, 6.9-17.0) |
10 cases in 4,041,396 doses 2.5/million (95% CI, 1.2-4.6) |
33 cases in 25,173,965 doses 1.3/million (95% CI, 0.9-1.8) |
| Brighton criteria (reassessed) | Levels 1-3 |
15 cases 7.9/million (95% CI, 4.4-13.1) |
5 cases 1.2/million (95% CI, 0.4-2.9) |
31 cases 1.2/million (95% CI, 0.8-1.8) |
| National Institute of Allergy and Infectious Disease | 4 cases 2.1/million (95% CI, 0.6-5.4) |
3 cases 1.5/million (95% CI, 0.2-2.2) |
18 cases 0.7/million (95% CI, 0.4-1.1) |
|
| World Allergy Organization | 10 cases 5.3/million (95% CI, 2.5-9.7) |
4 cases 1.0/million (95% CI, 0.3-2.5) |
25 cases 1.0/million (95% CI, 0.6-1.5) |
|